EMCC: Oral Anti-Angiogenesis Treatment Plus Chemotherapy Is Not More Efficacious Than Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer

Publication
Article
OncologyONCOLOGY Vol 25 No 12
Volume 25
Issue 12

This phase I/II trial assessed the efficacy of mFOLFOX6 with either BIBF 1120, an oral anti-angiogenesis agent, or with bevacizumab, an anti-angiogenesis antibody, in chemotherapy-naïve patients with metastatic colorectal cancer (mCRC). Patients were randomized 2:1 to the BIBF 1120 and bevacizumab arms, respectively.

This phase I/II trial assessed the efficacy of mFOLFOX6 with either BIBF 1120, an oral anti-angiogenesis agent, or with bevacizumab, an anti-angiogenesis antibody, in chemotherapy-nave patients with metastatic colorectal cancer (mCRC). Patients were randomized 2:1 to the BIBF 1120 and bevacizumab arms, respectively.

BIBF 1120 is an oral triple inhibitor of angiogenesis that had previously shown a favorable safety profile in mCRC patients, including reversible liver enzymes, mild hypertension, and mild gastrointestinal events.

Median progression-free survival was 10.6 months for both trial arms. 61.2% of patients in the BIBF 1120 arm compared with 53.7% of patients in the bevacizumab arm responded to the treatment. The median duration of response was 8.0 months, compared with 10.5 months in the BIBF 1120 and bevacizumab arms, respectively. The trial results were presented by Dr. Eric Van Cutsem from the University Hospital in Leuven, Belgium.

Slightly more hypertension and GI perforations were seen in the bevacizumab arm, compared with the BIBF 1120 arm (27% vs 18% and 12% vs 5%, respectively).

The overall survival and quality of life results are still being assessed for this trial. Dr. Cutsem concluded that the two treatment arms had similar tolerance and efficacy, but the BIBF 1120 arm had a lower frequency of serious side effects. Dr.Michel Ducreux of the Institut Gustave Roussy in Paris, France, the discussant for the trial data, noted that the study had "ambitious goals," as "angiogenesis is a very complex problem". He noted that this was the "first time that when you add a tyrosine kinase inhibitor to chemo, you are able to do it with without added toxicity." On the slight disparity in the number of GI perforations he stated that "for me, it's probably a piece of chance or lack of chance for bevacizumab." He pointed out that the numbers are very small and that the results favor antibodies over TKIs in colorectal cancer at this point. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content